HilleVax Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	29.36	26.66	16.71	5.76	1.3
Research & Development	109.5	106.68	45.91	10.01	0
Other Operating Expenses	15.33	0	2.5	37.66	0
Operating Expenses	154.18	133.35	65.11	53.43	1.3
Operating Income	-154.18	-133.35	-65.11	-53.43	-1.3
Interest Expense / Income	2.67	2.39	3.41	2.84	0.03
Other Expense / Income	-13.35	-12.17	91.28	46.14	0.78
Pretax Income	-143.51	-123.57	-159.81	-102.41	-2.1
Net Income	-143.51	-123.57	-159.81	-102.41	-2.1
Shares Outstanding (Basic)	48	41	27	6	4
Shares Outstanding (Diluted)	48	41	27	6	4
Shares Change	28.36%	49.55%	383.12%	28.65%	-
EPS (Basic)	-3.30	-3.04	-5.89	-18.22	-0.48
EPS (Diluted)	-3.30	-3.04	-5.89	-18.22	-0.48
Free Cash Flow	-111.75	-97.53	-66	-7.34	-1.27
Free Cash Flow Per Share	-2.31	-2.40	-2.43	-1.31	-0.29
EBITDA	-138.33	-119.02	-155.25	-99.56	-2.07
Depreciation & Amortization	2.5	2.16	1.15	0	0
EBIT	-140.84	-121.17	-156.4	-99.56	-2.07

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).